Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

NCT02036060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

119

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
DRUG: docetaxel 75 mg/m2 + prednisone 10 mg/d

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]